Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate withdrawal with tofacitinib MR 11 mg in rheumatoid arthritis
2016-001825-15Phase 3Completed
- Sponsor
- Pfizer
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tofacitinib in rheumatoid arthritis (RA) (2 arms), sponsored by Pfizer. Primary endpoint: Change in DAS28-4 (ESR) from Week 24 to Week 48. Started Dec 2016; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2016-001825-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001825-15.